Skip to content
Study details
Enrolling now

JUST BREATHE Trial

PPD Development, LP
NCT IDNCT06703073ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

600

Study length

about 3.3 years

Ages

18+

Locations

36 sites in AL, CA, CO +20

What this study is about

This trial is testing a treatment for ARDS, a serious lung condition. Participants will be randomly assigned to receive either a placebo or one of several different treatments.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cohort A: placebo
  • 2.Take Cohort A: vilobelimab
  • 3.Take Cohort B: paridiprubart
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

bevacizumab, vilobelimab

Drug routes

infusion, injection, intravenous

Endpoints

Secondary: Days of hospitalization up to and including Day 28, Improvements in oxygenation measured as change from baseline in PaO2/FiO2 ratio up to and including Day 28 (or discharge, whichever is earlier), Incidence and severity of adverse events (AEs) /adverse event of special interest (AESI) / serious adverse event (SAEs)